Generation of transgenic chicken through ovarian injection

Abstract

Background: Traditional DNA microinjection methods used in mammals are difficult to apply to avian species due to their unique reproductive characteristics. Genetic manipulation in chickens, particularly involving immature follicles within living ovaries, has not been extensively explored. This study seeks to establish an efficient method for generating transgenic chickens through ovarian injection, potentially bypassing the challenges associated with primordial germ cell (PGC) manipulation and fertilized egg microinjection.

Methods: Hens were anesthetized and underwent a surgical procedure to access the ovary for DNA injection into immature follicles. The study used liposomes to deliver GFP-expressing plasmids at various dosages. After injection, hens recovered, and their eggs were fertilized through artificial insemination.

Results: Transgenic chickens were successfully generated in one generation without needing G0 founders. The injection of 20 µg plasmid yielded the highest transgenic efficiency at 12.1%. GFP-positive embryos were confirmed through microscopy, and successful transgene expression was validated at the tissue level using immunostaining. TERT and GFP elements introduced in the G1 generation resulted in 4.1% positive transgene rates, as confirmed by PCR and Southern blotting.

Conclusion: This ovarian injection method offers a promising alternative for avian genetic manipulation, bypassing complex PGC procedures and enabling direct generation of G1 transgenic chickens. This technique simplifies the transgenic process for chickens and has the potential to be adapted for other avian species, especially those without established PGCs culture systems.

Keywords

avian species / gene manipulation / ovarian injection / transgenic chickens

References

[1] Mozdziak PE, Petitte JN. Status of transgenic chicken models for developmental biology. Dev Dyn. 2004;229:414-421.

[2] Lee HJ, Lee HC, Han JY. Germline modification and engineering in avian species. Mol Cells. 2015;38:743-749.

[3] Bahrami S, Amiri-Yekta A, Daneshipour A, et al. Designing a transgenic chicken: applying new approaches toward a promising bioreactor. Cell J. 2020;22:133-139.

[4] Lillico SG, Sherman A, McGrew MJ, et al. Oviduct-specific expression of two therapeutic proteins in transgenic hens. Proc Natl Acad Sci USA. 2007;104:1771-1776.

[5] Herron LR, Pridans C, Turnbull ML, et al. A chicken bioreactor for efficient production of functional cytokines. BMC Biotechnol. 2018;18:82.

[6] Kim YM, Park JS, Kim SK, et al. The transgenic chicken derived anti-CD20 monoclonal antibodies exhibits greater anti-cancer therapeutic potential with enhanced fc effector functions. Biomaterials. 2018;167:58-68.

[7] Lee J, Kim DH, Lee K. Current approaches and applications in avian genome editing. Int J Mol Sci. 2020;21(11):3937.

[8] Kojima Y, Okuzaki Y, Nishijima K, et al. Regulatory mechanism of chicken lysozyme gene expression in oviducts examined using transgenic technology. J Biosci Bioeng. 2021;131:453-459.

[9] Lillico SG, McGrew MJ, Sherman A, Sang HM. Transgenic chickens as bioreactors for protein-based drugs. Drug Discov Today. 2005;10:191-196.

[10] Bednarczyk M, Kozlowska I, Lakota P, Szczerba A, Stadnicka K, Kuwana T. Generation of transgenic chickens by the non-viral, cell-based method: effectiveness of some elements of this strategy. J Appl Genet. 2018;59:81-89.

[11] Nishijima K, Iijima S. Transgenic chickens. Develop Growth Differ. 2013;55:207-216.

[12] van de Lavoir MC, Diamond JH, Leighton PA, et al. Germline transmission of genetically modified primordial germ cells. Nature. 2006;441:766-769.

[13] Chojnacka-Puchta L, Kasperczyk K, Plucienniczak G, Sawicka D, Bednarczyk M. Primordial germ cells (PGCs) as a tool for creating transgenic chickens. Pol J Vet Sci. 2012;15:181-188.

[14] Kamihira M, Nishijima K, Iijima S. Transgenic birds for the production of recombinant proteins. Adv Biochem Eng Biotechnol. 2004;91:171-189.

[15] Han JY, Park YH. Primordial germ cell-mediated transgenesis and genome editing in birds. J Anim Sci Biotechnol. 2018;9:19.

[16] Sang H. Prospects for transgenesis in the chick. Mech Dev. 2004;121:1179-1186.

[17] Carsience RS, Clark ME, Verrinder Gibbins AM, Etches RJ. Germline chimeric chickens from dispersed donor blastodermal cells and compromised recipient embryos. Development. 1993;117:669-675.

[18] Kagami H, Tagami T, Matsubara Y, et al. The developmental origin of primordial germ cells and the transmission of the donor-derived gametes in mixed-sex germline chimeras to the offspring in the chicken. Mol Reprod Dev. 1997;48:501-510.

[19] Nakamura Y, Usui F, Miyahara D, et al. X-irradiation removes endogenous primordial germ cells (PGCs) and increases germline transmission of donor PGCs in chimeric chickens. J Reprod Dev. 2012;58:432-437.

[20] Larson MA. Pronuclear microinjection of one-cell embryos. Methods Mol Biol. 2020;2066:27-33.

[21] Chuang CK, Tu CF, Chen CH. Generation of mutant pigs by direct pronuclear microinjection of CRISPR/9 plasmid vectors. Bio Protoc. 2017;7:e2321.

[22] Pokhrel N, Ben-Tal Cohen E, Genin O, Sela-Donenfeld D, Cinnamon Y. Cellular and morphological characterization of blastoderms from freshly laid broiler eggs. Poult Sci. 2017;96:4399-4408.

[23] Naito M, Sasaki E, Ohtaki M, Sakurai M. Introduction of exogenous DNA into somatic and germ-cells of chickens by microinjection into the germinal disc of fertilized ova. Mol Reprod Dev. 1994;37:167-171.

[24] Sang H, Perry MM. Episomal replication of cloned DNA injected into the fertilised ovum of the hen, Gallus domesticus. Mol Reprod Dev. 1989;1:98-106.

[25] Wu XT, Shen WM, Zhang BJ, Meng AM. The genetic program of oocytes can be modified in the zebrafish ovary. J Mol Cell Biol. 2018;10:479-493.

[26] Rasys AM, Park S, Ball RE, Alcala AJ, Lauderdale JD, Menke DB. CRISPR-9 gene editing in lizards through microinjection of unfertilized oocytes. Cell Rep. 2019;28:2288-2292.

[27] An M, Raguram A, Du SW, et al. Engineered virus-like particles for transient delivery of prime editor ribonucleoprotein complexes in vivo. Nat Biotechnol. 2024;42:1526-1537.

[28] Banskota S, Raguram A, Suh S, et al. Engineered virus-like particles for efficient in vivo delivery of therapeutic proteins. Cell. 2022;185:250-265.

RIGHTS & PERMISSIONS

2024 The Author(s). Animal Models and Experimental Medicine published by John Wiley & Sons Australia, Ltd on behalf of The Chinese Association for Laboratory Animal Sciences.